Multicenter retrospective observational study for hepatitis B virus reactivation-related liver complications in HBsAg-positive patients with diffuse large B-cell lymphoma following rituximab-containing chemotherapy - Retrospective study for hepatitis B virus reactivation in HBsAg-positive lymphoma patients

Department of Hematology, National Cancer Center Hospital0 sites500 target enrollmentJanuary 9, 2017

Overview

No summary available.

Registry

who.int

Start Date

January 9, 2017

End Date

December 31, 2017

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

Department of Hematology, National Cancer Center Hospital

•Exclusion criteria for HBsAg\-positive group: 1\) Seropositive for hepatitis C virus 2\) Seropositive for human immunodeficiency virus 3\) Alanine transaminase level of 100 U/L or more at baseline 4\) Lymphoma involvement of central nervous system at diagnosis of DLBCL regardless of primary or secondary one 5\) Diagnosed as having intravascular lymphoma or primary testicular lymphoma 6\) Have a history of systemic chemotherapy for hematological malignancies or solid tumors 7\) Diagnosed as having decompensated cirrhosis or hepatocellular carcinoma at diagnosis of DLBCL or have a history of decompensated cirrhosis or hepatocellular carcinoma Exclusion criteria for HBsAg\-negative group: 1\) Seropositive for HBsAg before or at diagnosis of DLBCL 2\) Seropositive for hepatitis C virus 3\) Seropositive for human immunodeficiency virus 4\) Alanine transaminase level of 100 U/L or more at baseline 5\) Lymphoma involvement of central nervous system at diagnosis of DLBCL regardless of primary or secondary one 6\) Diagnosed as having intravascular lymphoma or primary testicular lymphoma 7\) Have a history of systemic chemotherapy for hematological malignancies or solid tumors 8\) Diagnosed as having decompensated cirrhosis or hepatocellular carcinoma at diagnosis of DLBCL or have a history of decompensated cirrhosis or hepatocellular carcinoma